Minerva Neurosciences, Inc. Amortization of Debt Discount (Premium)
Minerva Neurosciences, Inc. (NERV) reported Amortization of Debt Discount (Premium) of $38.04 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2020-03-09
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for the quarter ending 2018-09-30 was $1.40K, a 97.00% decline year-over-year.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for the quarter ending 2018-06-30 was $12.39K, a 78.31% decline year-over-year.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for the quarter ending 2018-03-31 was $24.25K, a 63.82% decline year-over-year.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for fiscal 2018 was $38.04K, a 81.58% decline from fiscal 2017.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for fiscal 2017 was $206.56K, a 40.60% decline from fiscal 2016.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for fiscal 2016 was $347.77K, a 7.86% decline from fiscal 2015.
- Minerva Neurosciences, Inc. amortization of debt discount (premium) for fiscal 2015 was $377.45K, a 80.67% decline from fiscal 2014.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $1.40K derived: sum of 2 quarters · filed 2020-03-09 | $13.79K derived: sum of 3 quarters · filed 2020-03-09 | $38.04K 10-K · filed 2020-03-09 |
| 2018-09-30 | $1.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $13.79K derived: sum of 2 quarters · filed 2019-11-04 | $38.04K 10-Q · filed 2019-11-04 | $73.78K derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $12.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $36.64K 10-Q · filed 2019-08-05 | $72.38K derived: sum of 3 quarters · filed 2019-08-05 | $119.07K derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | $24.25K 10-Q · filed 2019-05-06 | $59.99K derived: sum of 2 quarters · filed 2019-05-06 | $106.68K derived: sum of 3 quarters · filed 2019-05-06 | $163.78K derived: sum of 4 quarters · filed 2019-05-06 |
| 2017-12-31 | $35.74K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $82.43K derived: sum of 2 quarters · filed 2019-03-12 | $139.53K derived: sum of 3 quarters · filed 2019-03-12 | $206.56K 10-K · filed 2019-03-12 |
| 2017-09-30 | $46.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $103.79K derived: sum of 2 quarters · filed 2018-11-05 | $170.82K 10-Q · filed 2018-11-05 | $247.65K derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | $57.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $124.13K 10-Q · filed 2018-08-02 | $200.96K derived: sum of 3 quarters · filed 2018-08-02 | $285.77K derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $67.03K 10-Q · filed 2018-05-03 | $143.86K derived: sum of 2 quarters · filed 2018-05-03 | $228.67K derived: sum of 3 quarters · filed 2018-05-03 | $320.69K derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $76.83K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $161.64K derived: sum of 2 quarters · filed 2018-03-12 | $253.66K derived: sum of 3 quarters · filed 2018-03-12 | $347.77K 10-K · filed 2018-03-12 |
| 2016-09-30 | $84.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $176.83K derived: sum of 2 quarters · filed 2017-11-06 | $270.94K 10-Q · filed 2017-11-06 | $371.37K derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $92.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $186.13K 10-Q · filed 2017-08-03 | $286.56K derived: sum of 3 quarters · filed 2018-03-12 | $417.37K derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $94.12K 10-Q · filed 2017-05-04 | $194.55K derived: sum of 2 quarters · filed 2018-03-12 | $325.35K derived: sum of 3 quarters · filed 2018-03-12 | $404.45K derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $100.43K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $231.24K derived: sum of 2 quarters · filed 2018-03-12 | $310.33K derived: sum of 3 quarters · filed 2018-03-12 | $377.45K 10-K · filed 2018-03-12 |
| 2015-09-30 | $130.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $209.90K derived: sum of 2 quarters · filed 2016-11-03 | $277.02K 10-Q · filed 2016-11-03 | $277.02K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | $79.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $146.22K 10-Q · filed 2016-08-04 | $146.22K derived: sum of 3 quarters · filed 2017-03-13 | $149.28K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | $67.12K 10-Q · filed 2016-05-03 | $67.12K derived: sum of 2 quarters · filed 2017-03-13 | $70.19K derived: sum of 3 quarters · filed 2017-03-13 | $1.75M derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $3.06K derived: sum of 2 quarters · filed 2017-03-13 | $1.68M derived: sum of 3 quarters · filed 2017-03-13 | $1.95M 10-K · filed 2017-03-13 |
| 2014-09-30 | $3.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.68M derived: sum of 2 quarters · filed 2015-11-05 | $1.95M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.95M 10-Q · filed 2015-08-05 | ||
| 2014-03-31 | $274.31K 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | $36.23K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |